Increasing prevalence of hospital-acquired infections around the world is driving the global hospital-acquired infections treatment market says Fortune Business Insights in a report titled, “Hospital Acquired Infections Treatment Market Size, Share and Global Trend By Infection Type (Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections), By Treatment (Antibacterial, Antiviral, Antifungal), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026.” Rising awareness about emerging infections acquired during hospital admission is a factor expected to promote the global hospital-acquired infections treatment market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hospital-acquired-infections-treatment-market-101035
some of the key players in the Hospital Acquired Infections Treatment Market:
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer, Inc.
- Cipla Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd.
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hospital-acquired-infections-treatment-market-101035
Approval Of ZERBAXA® By The FDA Will Accelerate Growth
Merck, a leading global biopharmaceutical company known as MSD launched it’s supplemental new drug ZERBAXA® after receiving approval from the Food and Drug Administration. The new drug will be used for the treatment of hospital-acquired bacterial pneumonia along with ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The infection is generally caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens. The announcement of the new drug is predicted to boost the global hospital-acquired infections treatment growth owing to the drug’s properties to prevent serious and occasionally fatal hypersensitivity (anaphylactic) reactions. Further, the approval of NUZYRA (omadacycline) by the FDA is expected to aid the global hospital-acquired infections treatment revenue.
For instance, Paratek Pharmaceuticals, received FDA approval to use NUZYRA (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Moreover, FDA approval for the use of Avycaz is also predicted to contribute positively to hospital-acquired infections treatment market. For instance, Allergan received FDA approval to use Avycaz for the treatment of nosocomial pneumonia in patients aged 18 years or older.
Increasing R&D Investments will Boost Growth in North America
Geographically, the global hospital-acquired infections treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global hospital-acquired infections treatment market during the forecast period owing to increasing R&D investments by market key players to launch new treatment options. In Europe, rising awareness about hospital-acquired infections and the presence of many key players are likely to facilitate the hospital-acquired infections treatment market growth. Asia Pacific is expected to rise at a significant rate during the forecast period owing to the increasing patient population and improving healthcare infrastructure. The Middle East & Africa is expected to grow at a considerable rate due to the rising demand for cost-effective treatment options. The increasing prevalence of various chronic disease supported by large hospital admission of patients is also predicted to aid hospital-acquired infections treatment market during the forecast period.
Some of the major companies that are present in the global hospital-acquired infections treatment market report include Abbott, AstraZeneca, Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Cipla Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd., among others.
More Trending Topics from Fortune Business Insights: